TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02159183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Plus ESTA STL Roxolid implant
Description: The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Plus STL implant
Description: The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
Study: NCT01019603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene
Description: Topical Tazarotene foam applied daily for 22 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazaroc Gel
Description: Topical tazarotene gel applied daily for 22 days.
Study: NCT06139588

Intervention type: DEVICE
Intervention: acellular dermal matrix implant for breast reconstruction
Description: acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

Intervention type: DEVICE
Intervention: acellular dermal matrix implant for breast reconstruction
Description: acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

Intervention type: DEVICE
Intervention: acellular dermal matrix implant for breast reconstruction
Description: acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

Intervention type: DEVICE
Intervention: acellular dermal matrix implant for breast reconstruction
Description: acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

Intervention type: DEVICE
Intervention: acellular dermal matrix implant for breast reconstruction
Description: acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

Intervention type: DEVICE
Intervention: acellular dermal matrix implant for breast reconstruction
Description: acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

Intervention type: DEVICE
Intervention: acellular dermal matrix implant for breast reconstruction
Description: acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy

Intervention type: DEVICE
Intervention: acellular dermal matrix implant for breast reconstruction
Description: acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy
Study: NCT02345395

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Aneurysm Clipping
Description: All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aneurysm Clipping
Description: All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aneurysm Clipping
Description: All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
Study: NCT00834756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg Tablet
Description: 1 x 600mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax® 600 mg Tablet
Description: 1 x 600mg, single-dose fasting
Study: NCT01274988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Deep brain stimulation of bilateral nucleus accumbens

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: methadone maintenance treatment
Description: methadone maintenance treatment
Study: NCT03800251

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutricia PreOp - a clear, non-carbonated, lemon flavoured, carbohydrate drink that provides 0.5kcal/ml
Description: Fasting parturients at term, admitted for elective cesarean section and consent to partake in the study, will be given the intervention drink
Study: NCT04230083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest 2.0 mg Test Drug
Description: Bioequivalence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest 2.0 mg Reference Product
Description: Bioequivalence
Study: NCT03195205

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OraQuick HCV Rapid Antibody Test
Description: HCV Screening
Study: NCT00359905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: 8 mg daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily for 12 weeks
Study: NCT00661596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5 mg, 10 mg and 20 mg one hour prior to sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02676024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knowledge-based cognitive aid
Description: Trained on the use of a knowledge-based cognitive aid for pediatric cardiac arrests. Will be used by a dedicated team member (cognitive aid reader).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive aids with roles defined (CARD)
Description: Trained on the use of the cognitive aids with roles defined (CARD) system for pediatric cardiac arrests. Participants are given large identification cards to be worn, which enable the code leader to quickly recognize the individuals' purpose at the code. The card identifies specific tasks associated with the role, ensuring that the participant knows exactly what their task is. Will not have a dedicated team member during the scenario (cognitive aid reader).
Study: NCT03896893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin antisepsis
Description: 1% aqueous chlorhexidine gluconate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient
Description: Aquaphor skin cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient
Description: Aquaphor skin cream
Study: NCT02676024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated cognitive aids
Description: Trained on the use of the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid for pediatric cardiac arrests which will be used by a dedicated cognitive aid reader.
Study: NCT02545205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL)
Description: Intensive gait training with Hybrid Assistive Limb (HAL) is performed, 1 session/day, 4 days/week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective walking time with HAL).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional gait training
Description: The conventional gait training is performed according to current best evidence based practice and may include over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support and training of gait function in activities of daily living.
Study: NCT01162694

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Blood Glucose Monitoring
Description: The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
Study: NCT03050944

Intervention type: OTHER
Intervention: Lifestyle behaviour and dietary habits assessment
Description: Lifestyle behaviour and dietary habits assessment

Intervention type: OTHER
Intervention: Lifestyle behaviour and dietary habits assessment
Description: Lifestyle behaviour and dietary habits assessment
Study: NCT01435265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard nurse education
Description: Standard-of-care education from a dermatology nurse on the proper use of adalimumab

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard nurse education
Description: Standard-of-care education from a dermatology nurse on the proper use of adalimumab

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional nurse education
Description: Additional education from a nurse on the use of adalimumab. This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit. Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided. Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided. Subjects will also receive reminder phone calls to take each scheduled dose.
Study: NCT03713333

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital Health Device Diagnostics
Description: Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.~* Handheld imaging - focused echocardiographic examination (Butterfly IQ)~* Smartphone iECG for cardiac rhythm assessments (Alivecor)~* Blood Pressure (CloudDX)~* Oxygen Saturation (CloudDX)~* Weight (CloudDX)~* Point-of-Care Genetic Testing (Phosphorous)
Study: NCT02627066

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Volume Control
Description: Persistent reduction in post-dialysis weight and dietary sodium restriction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Volume Control + Exercise
Description: Volume reduction intervention and comprehensive exercise counseling
Study: NCT02785003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment.
Study: NCT01534858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prontosan Wound Gel X
Description: Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
Study: NCT03543488

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuromuscular and functional capacity tests
Description: The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuromuscular and functional capacity tests
Description: The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests.
Study: NCT04559711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening coverage and quality of nutrition services during ANC
Description: Intervention clusters will receive inputs both at facility level and community level. The supply side inputs will include efforts for improving facility readiness, quality of nutrition services during ANC, multiple micronutrient supplementation(MMS) and strengthening monitoring and supervision for ANC. On the other hand, community mobilization interventions will be carried out for demand creation. All public health facilities providing ANC services in the intervention area will be included; Union Health \& Family Welfare Center, Community Clinic and Satellite Clinic.
Study: NCT01613170

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Toviaz
Description: Toviaz 4mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toviaz
Description: Toviaz 4mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin
Description: Premarin cream 1 g per vagina twice weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thioguanine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Study: NCT02785003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid
Description: All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alvimopan
Description: All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
Study: NCT02883413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRT + Teach the Parent
Description: CRT sessions will occur for 45-60 minutes every day (excluding weekends) for 6-8 days while adolescents are in hospital. Adolescents will be given homework and asked to practice tasks each day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRT + Contact Control
Description: Adolescents will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). Adolescents will be able to choose 2 tasks from a list and be asked to engage in those tasks with their parents.
Study: NCT03251911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor (VX-770)
Description: of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
Study: NCT00102440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, orally, once daily for up to 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 120 mg, orally, once daily for up to 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
Study: NCT02109692

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: dosage of miRNA
Study: NCT00430118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vindesine
Study: NCT02714153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge Balloon
Description: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
Study: NCT01881425

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Surgery
Description: An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnFocus MicroShunt
Description: An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure.
Study: NCT04627038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: LY3556050 Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Given orally
Study: NCT02236247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivabradine
Description: 5 mg oral twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill (identical to ivabradine) will be administered twice daily
Study: NCT02976662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artificial shrinkage
Description: Artificially eliminated blastocoelic fluid before vitrification procedures.
Study: NCT01262469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib + capecitabine
Description: For Lapatinib: 5 tablets of 250 mg each, once daily, until disease progression or unacceptable toxicity occurence.~For Capecitabine: 850 mg/m2 twice a day from day 1 to 14 of cycle 1 and 1000 mg/m2 twice a day from day 1 to 14 of the next cycles.